MP48-08 SAFETY OF TESTOSTERONE THERAPY IN MEN WITH PROSTATE CANCER

Abstract

You have accessJournal of UrologySexual Function/Dysfunction/Andrology: Medical and Non-surgical1 Apr 2014MP48-08 SAFETY OF TESTOSTERONE THERAPY IN MEN WITH PROSTATE CANCER Ravi Kacker, Mariam Hult, William Conners, and Abraham Morgentaler Ravi KackerRavi Kacker More articles by this author , Mariam HultMariam Hult More articles by this author , William ConnersWilliam Conners More articles by this author , and Abraham MorgentalerAbraham Morgentaler More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2014.02.1482AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail Introduction and Objectives Testosterone therapy (TTh) in men with prostate cancer (PCa) remains controversial, and published clinical experience is limited. We report our experience with TTh in various categories of men with PCa. Methods A retrospective chart review identified 135 men (mean age 64 ± 9y) with PCa who started TTh between May 2004 and Janurary 2013 and were followed for at least 6 months. Of these, 33 (24.4%) were on active surveillance (AS), 93 (68.9%) has undergone definitive local treatment for PCa and were without biochemical recurrence at the start of TTh, and 9 (6.7%) were treated with TTh after known biochemical recurrence. Results Of 33 men on AS, 3 men (9.1%) had upgrading on subsequent biopsy and 29 (87.9%) remained on AS over a mean follow-up of 31.2 mo. For 53 (39.3%) men starting TTh after radical prostatectomy, no patients had biochemical disease recurrence (PSA > 0.2ng/dL) over 30 mo of follow-up. Forty (29.6%) patients underwent either brachytherapy or XRT and were followed for an average of 26.7mo. Of these, 2(5%) patients developed PSA 2ng/dL over nadir but had subsequent PSAs below this threshold. Two (5%) men treated with radiotherapy elected for adjuvant HIFU. For the 9 (6.7%) patients with biochemically recurrent disease prior to starting T therapy, PSA continued to rise in 6 men without symptomatic metastatic disease over 28.7 months of follow-up. There were no skeletal-related events, and no deaths from prostate cancer in any group. Overall, 121 (89.6%) men with PCa remained on TTh with most men discontinuing therapy for lack of efficacy or other non-oncologic reasons. Conclusions TTh does not appear to cause higher than expected rates of PCa progression. A large majority of men with PCa treated with TTh will elect to continue treatment indefinitely. © 2014FiguresReferencesRelatedDetails Volume 191Issue 4SApril 2014Page: e529-e530 Advertisement Copyright & Permissions© 2014MetricsAuthor Information Ravi Kacker More articles by this author Mariam Hult More articles by this author William Conners More articles by this author Abraham Morgentaler More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...